Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD - Wikidata - wikimedia - TriplyDB

Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD

Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD

http://www.wikidata.org/entity/Q34183741

about

Pharmacotherapy of Attention-Deficit Hyperactivity Disorder in Adolescents Psychometric validation of the Weiss Functional Impairment Rating Scale-Parent Report Form in children and adolescents with attention-deficit/hyperactivity disorder Clinical utility of guanfacine extended release in the treatment of ADHD in children and adolescents Guanfacine extended release adjunctive to a psychostimulant in the treatment of comorbid oppositional symptoms in children and adolescents with attention-deficit/hyperactivity disorder The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials.Clonidine extended-release: in attention-deficit hyperactivity disorder.A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability.Combined Stimulant and Guanfacine Administration in Attention-Deficit/Hyperactivity Disorder: A Controlled, Comparative Study.The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-a ADHD treatments, sleep, and sleep problems: complex associations Predictors of treatment response in adolescents with comorbid substance use disorder and attention-deficit/hyperactivity disorder.Pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: clinical strategies Safety and efficacy of clonidine and clonidine extended-release in the treatment of children and adolescents with attention deficit and hyperactivity disorders.Attention-deficit/hyperactivity disorder in young children: predictors of diagnostic stability.Metabolic, toxicological, and safety considerations for drugs used to treat ADHD.Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.Combination pharmacotherapy for psychiatric disorders in children and adolescents: prevalence, efficacy, risks and research needs.Background, clinical features and treatment of attention deficit hyperactivity disorder in children.Developments and challenges in the diagnosis and treatment of ADHD.Attention-deficit/hyperactivity disorder with inadequate response to stimulants: approaches to management.The safety of extended-release drug formulations for the treatment of ADHD.Psychopharmacological interventions in autism spectrum disorder.Safety, Tolerability and Efficacy of Drugs for Treating Behavioural Insomnia in Children with Attention-Deficit/Hyperactivity Disorder: A Systematic Review with Methodological Quality Assessment.An Evaluation on the Efficacy and Safety of Treatments for Attention Deficit Hyperactivity Disorder in Children and Adolescents: a Comparison of Multiple Treatments.Can sodium/hydrogen exchange inhibitors be repositioned for treating attention deficit hyperactivity disorder? An in silico approach.Efficacy and Tolerability of Different Interventions in Children and Adolescents with Attention Deficit Hyperactivity Disorder.Treatment of Children and Adolescents with Attention Deficit Hyperactivity Disorder and/or Tourette's Disorder with Clonidine Extended Release.Returning to Stimulants in Children with Treatment Resistant ADHD: A Case Series.A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD).

P2860

Q22241419-B2896039-063A-4545-9B03-D34D30CE1225 Q27303963-B7D9FD46-D90F-4EFA-B247-5F5CD9740840 Q28265059-61F08FB8-37D6-411D-8988-E1D5C2BE0B0A Q33782856-E13212E2-495A-4044-9672-E8A70D5187A0 Q33898415-ABDD396C-AA79-437C-B2A8-ACCA0574DC30 Q34213149-250C1B9C-E458-47EB-89DB-1D740BBA6FEC Q34650130-78D1793A-CFCD-4312-B4DA-018B9BF9CCC4 Q34677924-8C6308A0-09C9-490C-B60F-7E5C015CC466 Q35132674-65114761-FE86-4CEF-B8F3-ABBFDFD17728 Q36233163-FDE26C02-A850-4CA4-A078-165CFBA4CBAB Q36403699-30D999C5-0B22-44DA-A14D-64C803268F48 Q36740445-05EE7607-1A0E-485E-B08B-BE47855F6CE6 Q37589039-D0E3667F-3669-4DF9-86C4-73250B00DFC8 Q37664982-7DF67F0F-B2C2-40E3-8927-DC01C751EE41 Q37993127-AE13177D-D6A9-417F-9574-03CBC506B9D6 Q38011640-7F1DD2DD-C2A3-4BAA-916F-6B007CCBD0FD Q38060572-67792178-37D5-46F5-AA64-36B5A449C887 Q38113748-5C28E8E4-C1FA-4E4D-BD29-A3068DB68EE2 Q38122410-1E5628FA-B075-4F32-A7A9-28AA227F6EA8 Q38154181-0669CA8E-03E7-42C7-9991-7E464084807E Q38176839-39BD9084-3685-4B06-8998-9B66563953E9 Q38732635-029EFAF6-71EE-4175-8531-FCE75651B44F Q38739577-EA52169B-6B94-4462-8152-068E8DCADDCF Q39229424-974496F7-85B2-4000-B54A-3493F5FAB603 Q39293219-DCC244F3-70AE-4C76-8483-FA90ED4002B0 Q45824592-D721A993-90ED-4184-969B-65781A7D4D51 Q46584563-EC410953-9594-444B-AA84-B198ACA7FE5E Q49255458-7EF07E1C-40E1-449F-AF3E-84824E95ED6E Q50285351-373D6B52-6AF3-46B8-B305-DFCFFB7B1FE3 Q51738002-533C5641-BE16-4983-A9D6-21323F93D760

P2860

Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD

http://www.wikidata.org/entity/Q34183741

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Clonidine extended-release tab ...... dren and adolescents with ADHD

@ast

Clonidine extended-release tab ...... dren and adolescents with ADHD

@en

Clonidine extended-release tab ...... dren and adolescents with ADHD

@nl

type

label

Clonidine extended-release tab ...... dren and adolescents with ADHD

@ast

Clonidine extended-release tab ...... dren and adolescents with ADHD

@en

Clonidine extended-release tab ...... dren and adolescents with ADHD

@nl

prefLabel

Clonidine extended-release tab ...... dren and adolescents with ADHD

@ast

Clonidine extended-release tab ...... dren and adolescents with ADHD

@en

Clonidine extended-release tab ...... dren and adolescents with ADHD

@nl

P1433

Q34183741-32E15138-76FE-443C-9409-76895A1E3B88

P1476

Q34183741-468B2FAE-135F-4614-853C-3179E4A100AF

P2093

Q34183741-1B060E1F-4CCE-4BFD-BAF0-EAFF3304C114

Q34183741-1C1011B8-28E3-4B51-A570-BB570AE1A2E6

Q34183741-2E7844D2-43F8-420D-8125-82EF58625FFA

Q34183741-3AAAE4A0-DDDC-4A5E-BBC0-D4E7D709C9E9

Q34183741-6CABCD5A-1565-487B-B6F0-B0C0AA6C6F69

Q34183741-7BDB51AA-0446-4DE3-B176-76B3F92282D9

Q34183741-A27F8A84-D4EC-4C46-9D9E-CF97493DC8F8

P2860

Q34183741-2D660DA4-386E-4E50-9E64-A8F0C9D46EDC

Q34183741-3D624031-9220-4B9C-B95C-21CB9BF5F667

Q34183741-3DB7051C-7F91-43E4-85AB-82275DB0015D

Q34183741-437A3204-41BA-4A54-9888-E5A4CC6EE8E4

Q34183741-612B6D53-EC00-4579-AA03-824AD630B9A2

Q34183741-6834E096-1A12-49E9-91CA-5544018182E7

Q34183741-756CD6E1-730B-490F-887B-0FD2F0A68348

Q34183741-85681D0F-358C-418A-A659-87F7740F02BA

Q34183741-8B744AE5-8553-4CEF-AC51-659541DCA94C

Q34183741-8C92E4AB-877C-4FA7-86DB-4EE2B53D5A34

P304

Q34183741-536A3A10-7CCC-4F12-A959-21FE06A24B17

P31

Q34183741-8CEFE3F7-6B9A-4427-8F32-048788133922

P356

Q34183741-5C352490-883E-4C25-8E5C-4B43773224E3

P407

Q34183741-D890872F-B389-4509-9268-6A220934E3D6

P433

Q34183741-039A9A1A-D72E-42DF-9809-82728D1A355B

P478

Q34183741-AE7A79F7-803C-459E-93F1-7462DCC4EAB5

P577

Q34183741-319DB277-23D6-49C2-9F02-7AE7C4BB6703

P5875

Q34183741-CD269A40-7F3C-48E1-976E-F2724DEF7C73

P698

Q34183741-98E43064-FD92-4FE4-A75A-C361D7CE7878

P921

Q34183741-42469CF2-C648-4F17-92C1-390BBDEBC632

P932

Q34183741-D79C2C7C-051F-4BA7-8B8E-8650EBD1638D

P356

P1433

P1476

Clonidine extended-release tab ...... dren and adolescents with ADHD

@en

P2093

Matthew Brams

http://www.w3.org/2001/XMLSchema#string

Moise Khayrallah

http://www.w3.org/2001/XMLSchema#string

Rakesh Jain

http://www.w3.org/2001/XMLSchema#string

Robert L Findling

http://www.w3.org/2001/XMLSchema#string

Scott H Kollins

http://www.w3.org/2001/XMLSchema#string

Scott Segal

http://www.w3.org/2001/XMLSchema#string

Sharon B Wigal

http://www.w3.org/2001/XMLSchema#string

P2860

Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

Treatment of ADHD in children with tics: a randomized controlled trial

A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder

Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study.

Prevalence, recognition, and treatment of attention-deficit/hyperactivity disorder in a national sample of US children.

Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes.

Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.

Comorbid problems in ADHD: degree of association, shared endophenotypes, and formation of distinct subtypes. Implications for a future DSM

Anxiety and depressive disorders in attention deficit disorder with hyperactivity: new findings.

Management of children prescribed psychostimulant medication for attention deficit hyperactivity disorder in the Hunter region of NSW.

P304

e1406-13

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1542/PEDS.2010-1260

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

127

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51110703

http://www.w3.org/2001/XMLSchema#string

P698

21555501

http://www.w3.org/2001/XMLSchema#string

P921

P932

3387872

http://www.w3.org/2001/XMLSchema#string